| Display title | Chemistry:Rucaparib |
| Default sort key | Rucaparib |
| Page length (in bytes) | 16,793 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 807129 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Smart bot editor |
| Date of page creation | 03:10, 6 February 2024 |
| Latest editor | imported>Smart bot editor |
| Date of latest edit | 03:10, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is taken by mouth.
The most common side effects include tiredness or weakness, nausea... |
